OTOlivia B. Taylor

Olivia B. Taylor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olivia B. Taylor has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Colleen M. Cebulla

    The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA

    3 shared publications
  • Emma Schreiner

    The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA

    3 shared publications
  • Isabella Gray

    The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA

    3 shared publications
  • Lindsey Byrne

    Division of Human Genetics, Department of Internal Medicine The Ohio State University Columbus Ohio USA

    3 shared publications
  • Mohamed Helmy Abdel-Rahman

    Havener Eye Institute, Department of Ophthalmology and Visual Sciences, The Ohio State University Wexner Medical Center, Columbus, USA

    3 shared publications
  • Andy J. Fischer

    Department of Neuroscience, College of Medicine, The Ohio State University, Columbus, OH 43210, USA

    2 shared publications

Latest Publications

  • Open Access

    Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients

    by Lindsey Byrne, Isabella Gray, Kaylee Ramsey, Joseph McElroy, Emma Schreiner, Jenna Wolfe, Olivia B. Taylor, Frederick Davidorf, Colleen M. Cebulla, Mohamed H. Abdel‐Rahman

    Germline genetic testing is increasingly incorporated into the care of patients with uveal melanoma, yet optimal testing strategies remain unclear. This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021 and 9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multigene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2 ). Among unrelated individuals, the positive rate was 13% (8/69). Excluding carrier genes, the rate was 10.1% (7/69). Eight patients would have been missed if only tested for BAP1 per American Society of Clinical Oncology (ASCO) 2024 recommendations. There was no association between tumor size, stage, and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, these findings support genetic counseling for multigene panel testing in high‐risk uveal melanoma patients. Further studies of the impact of germline variants on UM disease outcome are warranted.

  • Open Access

    Multigene Panel Testing Outcomes in Patients with Uveal Melanoma: Implementation of National Guidelines

    by Lindsey Byrne, Isabella Gray, Kaylee Ramsey, Joseph McElroy, Emma Schreiner, Jenna Wolfe, Olivia B. Taylor, Frederick Davidorf, Colleen M. Cebulla, Mohamed H. Abdel-Rahman

    This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021-9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multi-gene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2) . Among unrelated individuals, the positive rate was12.9% (8/70). Excluding carrier genes, the rate was10% (7/70) Eight patients would have been missed if only tested for BAP1 per ASCO 2024 recommendations. There was no association between tumor size, stage and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, large panel testing, rather than BAP1 single gene testing, is recommended.

  • Open Access

    High Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome

    by Kaylee A. Ramsey, Lindsey Byrne, Olivia B. Taylor, Amr Soliman, Emma Schreiner, Isabella Gray, Alicia Latham, Rania Sheikh, Saman S. Ahmadian, Russell R. Lonser, et al.

    Background: BAP1 -tumor predisposition syndrome ( BAP1 -TPDS) is associated with four main cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, there are additional cancers found more rarely in BAP1 -TPDS patients. The aim of this study was to investigate the association, clinical, and pathologic characteristics of meningioma in BAP1 -TPDS. Methods: We conducted a retrospective chart review of meningiomas in two independent cohorts of patients with germline BAP1 pathogenic or likely pathogenic (P/LP) variants at The Ohio State University Wexner Medical Center and at the Memorial Sloan Kettering Cancer Center from October 1 st , 2010 date to April 21 st , 2025. Additionally, we conducted a literature review of meningioma case studies for individuals with germline BAP1 (P/LP) variants. Results: In a cohort of 237 subjects with BAP1 -TPDS, we identified 6.8% (16/237) with history of meningiomas. The average age of diagnosis was 45.8 years (17-71). For patients with available pathology, 61.5% (8/13) of the tumors were grade II/III. Patients with available tumor tissue 83.3% (5/6) showed evidence of BAP1 biallelic inactivation. Family history of meningioma was reported in 18.8% (3/16) of patients. Three cases of meningioma were identified during meningioma surveillance imaging. Published cases were consistent with the early age of onset, high-grade tumors, and clinical phenotype of tumors. Conclusions: This study provides additional evidence that high-grade brain and spinal meningiomas are part of the clinical spectrum of BAP1 -TPDS. Craniospinal imaging surveillance in the BAP1 -TPDS population should be considered starting around puberty, enabling early detection and management for individuals with BAP1 -TPDS. Key Points: High frequency of patients in our BAP1-TPDS cohort had meningiomas (6.8%) BAP1-TPDS meningiomas had rhabdoid and papillary histologic subtypes and high WHO grades These patients were diagnosed at a younger age compared to the average population There was a female predominance of meningioma in BAP1-TPDS patients BAP1-TPDS related meningiomas are at risk for higher rates of local recurrence, particularly rhabdoid histology Importance of the Study: BAP1-tumor predisposition syndrome ( BAP1 -TPDS) is a rare syndrome which is associated with four cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, our group has observed additional cancers in these patients, including meningioma. Here, we present a retrospective chart review of 16 patients with germline pathogenic BAP1 variants and meningioma, representing 6.8% of our entire cohort of BAP1 -TPDS cases. We report that BAP1-TPDS patients are at higher risk of developing high-grade meningiomas and are diagnosed at an earlier age than the general population. Three meningiomas and one meningothelial cyst were observed during surveillance imaging in asymptomatic patients. Patient and family cancer history included other BAP1 -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in BAP1 -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.

  • Open Access

    Sphingosine-1-phosphate signaling regulates the ability of Müller glia to become neurogenic, proliferating progenitor-like cells

    by Olivia B Taylor, Nicholas DeGroff, Heithem M El-Hodiri, Chengyu Gao, Andy J Fischer

    The purpose of these studies is to investigate how Sphingosine-1-phosphate (S1P) signaling regulates glial phenotype, dedifferentiation of Müller glia (MG), reprogramming into proliferating MG-derived progenitor cells (MGPCs), and neuronal differentiation of the progeny of MGPCs in the chick retina. We found that S1P-related genes are highly expressed by retinal neurons and glia, and levels of expression were dynamically regulated following retinal damage. Drug treatments that activate S1P receptor 1 (S1PR1) or increase levels of S1P suppressed the formation of MGPCs. Conversely, treatments that inhibit S1PR1 or decrease levels of S1P stimulated the formation of MGPCs. Inhibition of S1P receptors or S1P synthesis significantly enhanced the neuronal differentiation of the progeny of MGPCs. We report that S1P-related gene expression in MG is modulated by microglia and inhibition of S1P receptors or S1P synthesis partially rescues the loss of MGPC formation in damaged retinas missing microglia. Finally, we show that TGFβ/Smad3 signaling in the resting retina maintains S1PR1 expression in MG. We conclude that the S1P signaling is dynamically regulated in MG and MGPCs in the chick retina, and activation of S1P signaling depends, in part, on signals produced by reactive microglia.


  • Open Access

    ID factors regulate the ability of Müller glia to become proliferating neurogenic progenitor‐like cells

    by Olivia B. Taylor, Snehal P. Patel, Evan C. Hawthorn, Heithem M. El‐Hodiri, Andy J. Fischer

    The purpose of this study was to investigate how ID factors regulate the ability of Müller glia (MG) to reprogram into proliferating MG‐derived progenitor cells (MGPCs) in the chick retina. We found that ID1 is transiently expressed by maturing MG (mMG), whereas ID4 is maintained in mMG in embryonic retinas. In mature retinas, ID4 was prominently expressed by resting MG, but following retinal damage ID4 was rapidly upregulated and then downregulated in MGPCs. By contrast, ID1, ID2, and ID3 were low in resting MG and then upregulated in MGPCs. Inhibition of ID factors following retinal damage decreased numbers of proliferating MGPCs. Inhibition of IDs, after MGPC proliferation, significantly increased numbers of progeny that differentiated as neurons. In damaged or undamaged retinas inhibition of IDs increased levels of p21Cip1 in MG. In response to damage or insulin+FGF2 levels of CDKN1A message and p21Cip1 protein were decreased, absent in proliferating MGPCs, and elevated in MG returning to a resting phenotype. Inhibition of notch‐ or gp130/Jak/Stat‐signaling in damaged retinas increased levels of ID4 but not p21Cip1 in MG. Although ID4 is the predominant isoform expressed by MG in the chick retina, id1 and id2a are predominantly expressed by resting MG and downregulated in activated MG and MGPCs in zebrafish retinas. We conclude that ID factors have a significant impact on regulating the responses of MG to retinal damage, controlling the ability of MG to proliferate by regulating levels of p21Cip1, and suppressing the neurogenic potential of MGPCs.